Treatment of Alzheimer Disease by Continuous Intravenous Infusion of Physostigmine
作者:
Sanjay Asthana,
Kathleen Raffaele,
Annamaria Berardi,
Nigel Greig,
James Haxby,
Mark Schapiro,
Timothy Soncrant,
期刊:
Alzheimer Disease and Associated Disorders
(OVID Available online 1995)
卷期:
Volume 9,
issue 4
页码: 223-232
ISSN:0893-0341
年代: 1995
出版商: OVID
关键词: Alzheimer disease;Memory;Physostigmine;Steady-state infusion
数据来源: OVID
摘要:
Summary Physostigmine, a reversible and nonselective cholinesterase inhibitor, administered by steady-state, continuous intravenous infusion to carefully selected subjects with mild-moderate Alzheimer disease, produced significant but modest improvement in memory in five of nine subjects. Drug dosing was limited by the occurrence of adverse effects. Apparent tolerance to adverse effects was observed in two subjects when the dose of physostigmine was escalated slowly over at least 2 weeks. Steady-state cholinesterase inhibition by physostigmine appears to produce sustained cognitive improvement in some subjects with Alzheimer disease without substantially altering its therapeutic index.
点击下载:
PDF
(818KB)
返 回